MA56768B1 - Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase - Google Patents

Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase

Info

Publication number
MA56768B1
MA56768B1 MA56768A MA56768A MA56768B1 MA 56768 B1 MA56768 B1 MA 56768B1 MA 56768 A MA56768 A MA 56768A MA 56768 A MA56768 A MA 56768A MA 56768 B1 MA56768 B1 MA 56768B1
Authority
MA
Morocco
Prior art keywords
protein kinase
kinase inhibitors
quinoline derivatives
derivatives used
quinoline
Prior art date
Application number
MA56768A
Other languages
English (en)
Inventor
Dominique Surleraux
Claire AMIABLE
François-Xavier DIEUDONNÉ
Thierry Louat
Sabrina DEROO
Remi Guillon
Original Assignee
Hirundo Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hirundo Biosciences filed Critical Hirundo Biosciences
Publication of MA56768B1 publication Critical patent/MA56768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé approprié pour une utilisation en tant qu'inhibiteur de kinase
MA56768A 2019-08-08 2020-08-07 Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase MA56768B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19190898 2019-08-08
EP20751164.3A EP4010330B1 (fr) 2019-08-08 2020-08-07 Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase
PCT/EP2020/072322 WO2021023888A1 (fr) 2019-08-08 2020-08-07 Dérivés d'isoquinoline utilisés comme inhibiteurs de protéine kinase

Publications (1)

Publication Number Publication Date
MA56768B1 true MA56768B1 (fr) 2025-12-31

Family

ID=67658619

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56768A MA56768B1 (fr) 2019-08-08 2020-08-07 Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase

Country Status (27)

Country Link
US (1) US20220388979A1 (fr)
EP (2) EP4010330B1 (fr)
JP (1) JP7633702B2 (fr)
KR (1) KR102912166B1 (fr)
CN (1) CN114391009A (fr)
AU (1) AU2020324561B2 (fr)
BR (1) BR112022002222A2 (fr)
CA (1) CA3149846A1 (fr)
CL (1) CL2022000298A1 (fr)
CO (1) CO2022001860A2 (fr)
DK (1) DK4010330T3 (fr)
ES (1) ES3056661T3 (fr)
FI (1) FI4010330T3 (fr)
HR (1) HRP20251490T1 (fr)
IL (1) IL290314B2 (fr)
LT (1) LT4010330T (fr)
MA (1) MA56768B1 (fr)
MD (1) MD4010330T2 (fr)
MX (1) MX2022001467A (fr)
PE (1) PE20221034A1 (fr)
PH (1) PH12022550298A1 (fr)
PL (1) PL4010330T3 (fr)
PT (1) PT4010330T (fr)
RS (1) RS67544B1 (fr)
SI (1) SI4010330T1 (fr)
WO (1) WO2021023888A1 (fr)
ZA (1) ZA202202245B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503280A (ja) * 2020-12-29 2024-01-25 レボリューション メディシンズ インコーポレイテッド Ｓｏｓ１阻害剤及びその使用
CA3216785A1 (fr) * 2021-04-30 2022-11-03 Chengdu Anticancer Bioscience, Ltd. Composes de phenyl-o-quinoleine, de quinazoline, de thienopyridine, de thienopyrimidine, de pyrrolopyridine et de pyrrolopyrimidine ayant une activite anticancereuse
CN114217707B (zh) 2021-12-14 2024-01-19 北京字跳网络技术有限公司 分享方法、装置、电子设备和存储介质
CN120239701A (zh) * 2022-11-24 2025-07-01 Bci制药公司 作为蛋白激酶抑制剂的吡啶衍生物
CN116970567A (zh) * 2023-05-11 2023-10-31 宁波熙宁检测技术有限公司 一种稳转细胞株、构建方法及其应用
CN121219264A (zh) * 2023-05-12 2025-12-26 正大天晴药业集团股份有限公司 含有芳香双并环的化合物
WO2025021943A1 (fr) * 2023-07-26 2025-01-30 Neuralis Quinazolinone, benzoxazinone et dérivés de benzoxazépinone utilisés en tant qu'inhibiteurs de protéine kinase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843066A (en) 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
AU2002303023A1 (en) 2002-06-05 2003-12-22 Metabolic Engineering Laboratories Co., Ltd. Signals and molecular species involved in senescence
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20050250789A1 (en) 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AU2007245495A1 (en) 2006-04-26 2007-11-08 Astex Therapeutics Limited Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
JP2012504606A (ja) * 2008-10-01 2012-02-23 ラディック インスティテュート フォー キャンサー リサーチ 癌の治療方法
WO2011090738A2 (fr) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
PT2707359T (pt) * 2011-05-12 2017-01-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos ativos como inibidores de quinase
WO2016055982A1 (fr) * 2014-10-10 2016-04-14 Acerta Pharma B.V. Composés quinoléine et quinazoline
WO2016161952A1 (fr) * 2015-04-07 2016-10-13 广东众生药业股份有限公司 Inhibiteur de la tyrosine kinase et composition pharmaceutique le comprenant
WO2017049462A1 (fr) * 2015-09-22 2017-03-30 合肥中科普瑞昇生物医药科技有限公司 Nouvel inhibiteur de la kinase flt3 et ses utilisations
MX2020002611A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.

Also Published As

Publication number Publication date
EP4010330B1 (fr) 2025-10-01
SI4010330T1 (sl) 2026-03-31
RS67544B1 (sr) 2026-01-30
MD4010330T2 (ro) 2026-03-31
PT4010330T (pt) 2025-12-23
CL2022000298A1 (es) 2022-11-25
EP4628083A3 (fr) 2026-04-01
EP4628083A2 (fr) 2025-10-08
IL290314A (en) 2022-04-01
JP2022548820A (ja) 2022-11-22
ES3056661T3 (en) 2026-02-23
ZA202202245B (en) 2024-06-26
DK4010330T3 (da) 2025-12-22
PL4010330T3 (pl) 2026-03-16
KR102912166B1 (ko) 2026-01-15
KR20220066258A (ko) 2022-05-24
AU2020324561A1 (en) 2022-03-17
IL290314B1 (en) 2024-11-01
WO2021023888A8 (fr) 2021-12-09
LT4010330T (lt) 2026-03-10
MX2022001467A (es) 2022-05-06
CN114391009A (zh) 2022-04-22
HRP20251490T1 (hr) 2026-01-02
CO2022001860A2 (es) 2022-06-10
EP4010330A1 (fr) 2022-06-15
AU2020324561B2 (en) 2025-12-18
FI4010330T3 (fi) 2025-12-17
PE20221034A1 (es) 2022-06-17
WO2021023888A1 (fr) 2021-02-11
CA3149846A1 (fr) 2021-02-11
BR112022002222A2 (pt) 2022-06-07
JP7633702B2 (ja) 2025-02-20
PH12022550298A1 (en) 2023-04-24
US20220388979A1 (en) 2022-12-08
IL290314B2 (en) 2025-03-01

Similar Documents

Publication Publication Date Title
MA56768B1 (fr) Dérivés de quinoline utilisés comme inhibiteurs de protéine kinase
CL2022001731A1 (es) Inhibidores de egfr.
MA52948B1 (fr) Composés
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA42109A (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MA56208A (fr) Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MX2020014097A (es) Lipidos novedosos.
EP4210683A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine cbp/ep300
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
EP4223754A4 (fr) Composé en tant qu'inhibiteur de la kinase akt
MA44781B1 (fr) Composé hétérocyclique condensé
EP4037687A4 (fr) Composés de benzoxazinone utilisés comme inhibiteurs doubles de klk5/7
MA38559B1 (fr) Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
SA522432879B1 (ar) صور متعددة الأشكال من مركب ترايازول مضاد للفطريات pc945
MA52891A (fr) Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase
MA58104B1 (fr) Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine
MA55074A (fr) Dérivés de pyrazolopyridine utilisés comme inhibiteurs de pask